vs
EXACT SCIENCES CORP（EXAS）与帕兰提尔科技（PLTR）财务数据对比。点击上方公司名可切换其他公司
帕兰提尔科技的季度营收约是EXACT SCIENCES CORP的1.9倍（$1.6B vs $878.4M），帕兰提尔科技净利率更高（53.3% vs -9.8%，领先63.1%），帕兰提尔科技同比增速更快（84.7% vs 23.1%），过去两年帕兰提尔科技的营收复合增速更高（55.2% vs 17.4%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
帕兰提尔科技是美国上市企业，专注研发数据集成与分析平台，为政府机构、军方及各行业企业提供多源数据整合分析能力。旗下核心产品Gotham与Foundry可打通相互孤立的数据库，广泛支撑情报作业、反恐分析、执法工作及企业级数据分析场景。
EXAS vs PLTR — 直观对比
营收规模更大
PLTR
是对方的1.9倍
$878.4M
营收增速更快
PLTR
高出61.6%
23.1%
净利率更高
PLTR
高出63.1%
-9.8%
两年增速更快
PLTR
近两年复合增速
17.4%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $1.6B |
| 净利润 | $-86.0M | $870.5M |
| 毛利率 | 70.1% | 86.8% |
| 营业利润率 | -9.4% | 46.2% |
| 净利率 | -9.8% | 53.3% |
| 营收同比 | 23.1% | 84.7% |
| 净利润同比 | 90.1% | 306.7% |
| 每股收益（稀释后） | $-0.45 | $0.34 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASPLTR
| Q1 26 | — | $1.6B | ||
| Q4 25 | $878.4M | $1.4B | ||
| Q3 25 | $850.7M | $1.2B | ||
| Q2 25 | $811.1M | $1.0B | ||
| Q1 25 | $706.8M | $883.9M | ||
| Q4 24 | $713.4M | $827.5M | ||
| Q3 24 | $708.7M | $725.5M | ||
| Q2 24 | $699.3M | $678.1M |
净利润EXASPLTR
| Q1 26 | — | $870.5M | ||
| Q4 25 | $-86.0M | $608.7M | ||
| Q3 25 | $-19.6M | $475.6M | ||
| Q2 25 | $-1.2M | $326.7M | ||
| Q1 25 | $-101.2M | $214.0M | ||
| Q4 24 | $-864.6M | $79.0M | ||
| Q3 24 | $-38.2M | $143.5M | ||
| Q2 24 | $-15.8M | $134.1M |
毛利率EXASPLTR
| Q1 26 | — | 86.8% | ||
| Q4 25 | 70.1% | 84.6% | ||
| Q3 25 | 68.6% | 82.4% | ||
| Q2 25 | 69.3% | 80.8% | ||
| Q1 25 | 70.8% | 80.4% | ||
| Q4 24 | 69.0% | 78.9% | ||
| Q3 24 | 69.4% | 79.8% | ||
| Q2 24 | 69.8% | 81.0% |
营业利润率EXASPLTR
| Q1 26 | — | 46.2% | ||
| Q4 25 | -9.4% | 40.9% | ||
| Q3 25 | -3.0% | 33.3% | ||
| Q2 25 | -0.3% | 26.8% | ||
| Q1 25 | -13.6% | 19.9% | ||
| Q4 24 | -122.8% | 1.3% | ||
| Q3 24 | -5.6% | 15.6% | ||
| Q2 24 | -3.8% | 15.5% |
净利率EXASPLTR
| Q1 26 | — | 53.3% | ||
| Q4 25 | -9.8% | 43.3% | ||
| Q3 25 | -2.3% | 40.3% | ||
| Q2 25 | -0.1% | 32.6% | ||
| Q1 25 | -14.3% | 24.2% | ||
| Q4 24 | -121.2% | 9.5% | ||
| Q3 24 | -5.4% | 19.8% | ||
| Q2 24 | -2.3% | 19.8% |
每股收益（稀释后）EXASPLTR
| Q1 26 | — | $0.34 | ||
| Q4 25 | $-0.45 | $0.24 | ||
| Q3 25 | $-0.10 | $0.18 | ||
| Q2 25 | $-0.01 | $0.13 | ||
| Q1 25 | $-0.54 | $0.08 | ||
| Q4 24 | $-4.69 | $0.03 | ||
| Q3 24 | $-0.21 | $0.06 | ||
| Q2 24 | $-0.09 | $0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $2.3B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $8.6B |
| 总资产 | $5.9B | $10.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASPLTR
| Q1 26 | — | $2.3B | ||
| Q4 25 | $964.7M | $7.2B | ||
| Q3 25 | $1.0B | $6.4B | ||
| Q2 25 | $858.4M | $6.0B | ||
| Q1 25 | $786.2M | $5.4B | ||
| Q4 24 | $1.0B | $5.2B | ||
| Q3 24 | $1.0B | $4.6B | ||
| Q2 24 | $946.8M | $4.0B |
股东权益EXASPLTR
| Q1 26 | — | $8.6B | ||
| Q4 25 | $2.4B | $7.4B | ||
| Q3 25 | $2.5B | $6.6B | ||
| Q2 25 | $2.5B | $5.9B | ||
| Q1 25 | $2.4B | $5.4B | ||
| Q4 24 | $2.4B | $5.0B | ||
| Q3 24 | $3.2B | $4.5B | ||
| Q2 24 | $3.2B | $4.1B |
总资产EXASPLTR
| Q1 26 | — | $10.2B | ||
| Q4 25 | $5.9B | $8.9B | ||
| Q3 25 | $5.9B | $8.1B | ||
| Q2 25 | $5.8B | $7.4B | ||
| Q1 25 | $5.7B | $6.7B | ||
| Q4 24 | $5.9B | $6.3B | ||
| Q3 24 | $6.7B | $5.8B | ||
| Q2 24 | $6.7B | $5.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $899.2M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | — |
| 自由现金流率自由现金流/营收 | 13.7% | — |
| 资本支出强度资本支出/营收 | 3.6% | — |
| 现金转化率经营现金流/净利润 | — | 1.03× |
| 过去12个月自由现金流最近4个季度 | $356.8M | — |
8季度趋势，按日历期对齐
经营现金流EXASPLTR
| Q1 26 | — | $899.2M | ||
| Q4 25 | $151.7M | $777.3M | ||
| Q3 25 | $219.9M | $507.7M | ||
| Q2 25 | $89.0M | $539.3M | ||
| Q1 25 | $30.8M | $310.3M | ||
| Q4 24 | $47.1M | $460.3M | ||
| Q3 24 | $138.7M | $419.8M | ||
| Q2 24 | $107.1M | $144.2M |
自由现金流EXASPLTR
| Q1 26 | — | — | ||
| Q4 25 | $120.4M | $764.0M | ||
| Q3 25 | $190.0M | $500.9M | ||
| Q2 25 | $46.7M | $531.6M | ||
| Q1 25 | $-365.0K | $304.1M | ||
| Q4 24 | $10.7M | $457.2M | ||
| Q3 24 | $112.6M | $415.8M | ||
| Q2 24 | $71.2M | $141.3M |
自由现金流率EXASPLTR
| Q1 26 | — | — | ||
| Q4 25 | 13.7% | 54.3% | ||
| Q3 25 | 22.3% | 42.4% | ||
| Q2 25 | 5.8% | 53.0% | ||
| Q1 25 | -0.1% | 34.4% | ||
| Q4 24 | 1.5% | 55.3% | ||
| Q3 24 | 15.9% | 57.3% | ||
| Q2 24 | 10.2% | 20.8% |
资本支出强度EXASPLTR
| Q1 26 | — | — | ||
| Q4 25 | 3.6% | 0.9% | ||
| Q3 25 | 3.5% | 0.6% | ||
| Q2 25 | 5.2% | 0.8% | ||
| Q1 25 | 4.4% | 0.7% | ||
| Q4 24 | 5.1% | 0.4% | ||
| Q3 24 | 3.7% | 0.5% | ||
| Q2 24 | 5.1% | 0.4% |
现金转化率EXASPLTR
| Q1 26 | — | 1.03× | ||
| Q4 25 | — | 1.28× | ||
| Q3 25 | — | 1.07× | ||
| Q2 25 | — | 1.65× | ||
| Q1 25 | — | 1.45× | ||
| Q4 24 | — | 5.83× | ||
| Q3 24 | — | 2.92× | ||
| Q2 24 | — | 1.08× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
PLTR
暂无分部数据
